Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma

Survival in a phase III, randomized, double-blind study of dacarbazine with or without oblimersen (Bcl-2 antisense) in patients with advanced melanoma and low-normal serum lactate dehydrogenase (LDH; AGENDA).

(2017) A. Y. Bedikian et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).

(2017) Mario Sznol et al.   JOURNAL OF CLINICAL ONCOLOGY

OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.

(2017) Robert Hans Ingemar Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

NRAS mutant melanoma – undrugable?

(2015) Christian Posch et al.   Oncotarget

Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes

(2013) H. Henary et al.   ANNALS OF ONCOLOGY

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

(2013) J. D. Wolchok et al.   ANNALS OF ONCOLOGY

Common pathways to tumor rejection

(2013) Ena Wang et al.   Annals of the New York Academy of Sciences

Functionalized carbon nanotubes as immunomodulator systems

(2013) Mario Pescatori et al.   BIOMATERIALS

IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes

(2013) D Murtas et al.   BRITISH JOURNAL OF CANCER

CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2

(2013) D Bedognetti et al.   BRITISH JOURNAL OF CANCER

Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund’s adjuvant, with or without peptide

(2013) Elise P. Salerno et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

In Vivo MAPK Reporting Reveals the Heterogeneity in Tumoral Selection of Resistance to RAF Inhibitors

(2013) K. J. Basile et al.   CANCER RESEARCH

OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients

(2013) B. D. Curti et al.   CANCER RESEARCH

Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination

(2013) I. Melero et al.   CLINICAL CANCER RESEARCH

Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies

(2013) M. J. Besser et al.   CLINICAL CANCER RESEARCH

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Agonistic CD40 Antibodies and Cancer Therapy

(2013) R. H. Vonderheide et al.   CLINICAL CANCER RESEARCH

Vaccines against advanced melanoma

(2013) Tatiana Blanchard et al.   CLINICS IN DERMATOLOGY

Combining cancer immunotherapy and targeted therapy

(2013) Antoni Ribas et al.   CURRENT OPINION IN IMMUNOLOGY

Update on the role of ipilimumab in melanoma and first data on new combination therapies

(2013) Michele Maio et al.   CURRENT OPINION IN ONCOLOGY

Immune alterations in malignant melanoma and current immunotherapy concepts

(2013) Alexei Shimanovsky et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Protein kinase inhibitors in melanoma

(2013) Thomas K Eigentler et al.   EXPERT OPINION ON PHARMACOTHERAPY

Increasing immunogenicity of cancer vaccines to improve their clinical outcome

(2013) Giorgio Parmiani et al.   Expert Review of Vaccines

The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures

(2013) Jérôme Galon et al.   IMMUNITY

Deciphering and Reversing Tumor Immune Suppression

(2013) Greg T. Motz et al.   IMMUNITY

Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance

(2013) Laurence Zitvogel et al.   IMMUNITY

MERTK receptor tyrosine kinase is a therapeutic target in melanoma

(2013) Jennifer Schlegel et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

(2013) Antoni Ribas et al.   JOURNAL OF CLINICAL ONCOLOGY

Prediction of Response to Anticancer Immunotherapy Using Gene Signatures

(2013) Ena Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

(2013) Wim H.J. Kruit et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma

(2013) Mark E. Dudley et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma

(2013) Paolo A. Ascierto et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

(2013) Fernando Ulloa-Montoya et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma

(2013) Antonio Daponte et al.   Journal of Translational Medicine

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma

(2013) Maria Colombino et al.   Journal of Translational Medicine

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study

(2013) Caroline Robert et al.   LANCET ONCOLOGY

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

(2013) Paolo A Ascierto et al.   LANCET ONCOLOGY

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

(2013) Luana Calabrò et al.   LANCET ONCOLOGY

BACH2 represses effector programs to stabilize Treg-mediated immune homeostasis

(2013) Rahul Roychoudhuri et al.   NATURE

Reassessing target antigens for adoptive T-cell therapy

(2013) Christian S Hinrichs et al.   NATURE BIOTECHNOLOGY

Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion

(2013) Yared Hailemichael et al.   NATURE MEDICINE

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

(2013) Howard L. Kaufman et al.   Nature Reviews Clinical Oncology

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hepatotoxicity with Combination of Vemurafenib and Ipilimumab

(2013) Antoni Ribas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo

(2013) C. Posch et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment

(2013) N. Iida et al.   SCIENCE

TERT Promoter Mutations in Familial and Sporadic Melanoma

(2013) S. Horn et al.   SCIENCE

Highly Recurrent TERT Promoter Mutations in Human Melanoma

(2013) F. W. Huang et al.   SCIENCE

MEK Inhibition in the Treatment of Advanced Melanoma

(2013) April K. S. Salama et al.   Current Oncology Reports

Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors

(2013) E. J. Morris et al.   Cancer Discovery

Carbon nanotubes as a novel tool for vaccination against infectious diseases and cancer

(2013) Riccardo Gottardi et al.   JOURNAL OF NANOBIOTECHNOLOGY

Strong emerging rationale for combining oncogene-targeted agents with immunotherapy

(2013) Yan Yang et al.   OncoImmunology

Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab

(2013) Jianda Yuan et al.   Journal for ImmunoTherapy of Cancer

Therapeutic efficacy of combined blockade of CTLA-4 +/- PD-L1 +/- IDO is associated with re-activation of T cells directly within the tumor microenvironment

(2013) Stefani Spranger et al.   Journal for ImmunoTherapy of Cancer

The stable traits of melanoma genetics: an alternate approach to target discovery

(2012) Tara L Spivey et al.   BMC GENOMICS

Reflections upon human cancer immune responsiveness to T cell-based therapy

(2012) Ena Wang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)

(2012) K. A. Margolin et al.   CLINICAL CANCER RESEARCH

Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

(2012) J. S. Khalili et al.   CLINICAL CANCER RESEARCH

CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma

(2012) P. A. Prieto et al.   CLINICAL CANCER RESEARCH

BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice

(2012) C. Liu et al.   CLINICAL CANCER RESEARCH

Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients

(2012) L. G. Radvanyi et al.   CLINICAL CANCER RESEARCH

Bevacizumab Advanced Melanoma (BEAM) Was a Positive Trial

(2012) David R. Minor   JOURNAL OF CLINICAL ONCOLOGY

BRAF/NRASMutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma

(2012) Maria Colombino et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma

(2012) Keith T. Flaherty et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

(2012) Kevin B. Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

Melanoma: New Insights and New Therapies

(2012) Vasiliki A. Nikolaou et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Therapeutic Cancer Vaccines: Current Status and Moving Forward

(2012) J. Schlom   JNCI-Journal of the National Cancer Institute

c-KIT receptor expression is strictly associated with the biological behaviour of thyroid nodules

(2012) Sara Tomei et al.   Journal of Translational Medicine

IRF5 gene polymorphisms in melanoma

(2012) Lorenzo Uccellini et al.   Journal of Translational Medicine

Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)

(2012) Thomas F Gajewski et al.   Journal of Translational Medicine

The role of BRAF V600 mutation in melanoma

(2012) Paolo A Ascierto et al.   Journal of Translational Medicine

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

(2012) Anna Maria Di Giacomo et al.   LANCET ONCOLOGY

Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population

(2012) Sara Tomei et al.   MEDICAL ONCOLOGY

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

(2012) J. G. Greger et al.   MOLECULAR CANCER THERAPEUTICS

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dual Anti-OX40/IL-2 Therapy Augments Tumor Immunotherapy via IL-2R-Mediated Regulation of OX40 Expression

(2012) William L. Redmond et al.   PLoS One

A Multi-Factorial Genetic Model for Prognostic Assessment of High Risk Melanoma Patients Receiving Adjuvant Interferon

(2012) Ena Wang et al.   PLoS One

Functionalized multiwalled carbon nanotubes as ultrasound contrast agents

(2012) L. G. Delogu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Vaccines for Melanoma and Renal Cell Carcinoma

(2012) Howard L. Kaufman   SEMINARS IN ONCOLOGY

Correlates Between Host and Viral Transcriptional Program Associated with Different Oncolytic Vaccinia Virus Isolates

(2012) Jennifer Reinboth et al.   Human Gene Therapy Methods

A genetic inference on cancer immune responsiveness

(2012) Ena Wang et al.   OncoImmunology

Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68

(2011) Maria Libera Ascierto et al.   BMC CANCER

An immune-active tumor microenvironment favors clinical response to ipilimumab

(2011) Rui-Ru Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3+)-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates

(2011) N. Poirier et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the Treatment of Metastatic Melanoma

(2011) G. R. Weiss et al.   CLINICAL CANCER RESEARCH

Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma

(2011) J. Fruehauf et al.   CLINICAL CANCER RESEARCH

New Challenges in Endpoints for Drug Development in Advanced Melanoma

(2011) A. Ribas et al.   CLINICAL CANCER RESEARCH

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

(2011) James S. Wilmott et al.   CLINICAL CANCER RESEARCH

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

(2011) J. M. Kirkwood et al.   CLINICAL CANCER RESEARCH

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

(2011) S. A. Rosenberg et al.   CLINICAL CANCER RESEARCH

Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma

(2011) Xiang-Yang Wang et al.   EXPERT OPINION ON PHARMACOTHERAPY

Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes

(2011) Rafael Carretero et al.   INTERNATIONAL JOURNAL OF CANCER

KIT as a Therapeutic Target in Metastatic Melanoma

(2011) Richard D. Carvajal   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification

(2011) Jun Guo et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma

(2011) Ahmad A. Tarhini et al.   JOURNAL OF CLINICAL ONCOLOGY

BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma

(2011) Kevin B. Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma

(2011) Richard W. Joseph et al.   JOURNAL OF IMMUNOTHERAPY

The trouble with translational medicine

(2011) Francesco M. Marincola   JOURNAL OF INTERNAL MEDICINE

Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis

(2011) Tara L Spivey et al.   Journal of Translational Medicine

An immunologic portrait of cancer

(2011) Maria Ascierto et al.   Journal of Translational Medicine

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

(2011) Omid Hamid et al.   Journal of Translational Medicine

Combination therapy: the next opportunity and challenge of medicine

(2011) Paolo A Ascierto et al.   Journal of Translational Medicine

A human memory T cell subset with stem cell–like properties

(2011) Luca Gattinoni et al.   NATURE MEDICINE

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

(2011) Douglas J. Schwartzentruber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects

(2011) C. Garbe et al.   ONCOLOGIST

Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2010) R. Dummer et al.   ANNALS OF ONCOLOGY

Control of Immunity by the TNFR-Related Molecule OX40 (CD134)

(2010) Michael Croft   Annual Review of Immunology

A Mouse Model of Melanoma Driven by Oncogenic KRAS

(2010) C. Milagre et al.   CANCER RESEARCH

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

(2010) A. Boni et al.   CANCER RESEARCH

Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors

(2010) M. Del Vecchio et al.   CLINICAL CANCER RESEARCH

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

(2010) W. D. Stein et al.   CLINICAL CANCER RESEARCH

Gene-expression profiling in vaccine therapy and immunotherapy for cancer

(2010) Davide Bedognetti et al.   Expert Review of Vaccines

Therapeutic cancer vaccines: are we there yet?

(2010) Christopher A. Klebanoff et al.   IMMUNOLOGICAL REVIEWS

Immunologic therapy targeting metastatic melanoma: Allovectin-7®

(2010) Rozina Chowdhery et al.   Immunotherapy

Immunotherapy for Melanoma: Current Status and Perspectives

(2010) Doru T. Alexandrescu et al.   JOURNAL OF IMMUNOTHERAPY

The Farnesyl Transferase Inhibitor Lonafarnib Inhibits mTOR Signaling and Enforces Sorafenib-Induced Apoptosis in Melanoma Cells

(2010) Heike Niessner et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Vertical Inhibition of the mTORC1/mTORC2/PI3K Pathway Shows Synergistic Effects against Melanoma In Vitro and In Vivo

(2010) Johannes Werzowa et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The GIST paradigm: lessons for other kinase-driven cancers

(2010) Cristina R Antonescu   JOURNAL OF PATHOLOGY

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

(2010) Chrystelle Brignone et al.   Journal of Translational Medicine

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

(2010) C. Krieg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clinical Development of the Anti–CTLA-4 Antibody Tremelimumab

(2010) Antoni Ribas   SEMINARS IN ONCOLOGY

Targeting angiogenesis in melanoma: prospects for the future

(2010) P.G. Corrie et al.   Therapeutic Advances in Medical Oncology

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

(2009) Axel Hauschild et al.   JOURNAL OF CLINICAL ONCOLOGY

Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy

(2009) Marianna Sabatino et al.   JOURNAL OF CLINICAL ONCOLOGY

Main roads to melanoma

(2009) Giuseppe Palmieri et al.   Journal of Translational Medicine

MEK1 mutations confer resistance to MEK and B-RAF inhibition

(2009) C. M. Emery et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular Pathogenesis of Cutaneous Melanocytic Neoplasms

(2008) Nageatte Ibrahim et al.   Annual Review of Pathology-Mechanisms of Disease

Phase II trial of imatinib mesylate in patients with metastatic melanoma

(2008) K B Kim et al.   BRITISH JOURNAL OF CANCER

Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines

(2008) F. O. Smith et al.   CLINICAL CANCER RESEARCH

KIT Gene Mutations and Copy Number in Melanoma Subtypes

(2008) C. Beadling et al.   CLINICAL CANCER RESEARCH

Spontaneous and treatment-induced cancer rejection in humans

(2008) Ena Wang et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

The role of vaccine therapy in the treatment of melanoma

(2008) Marko Lens   EXPERT OPINION ON BIOLOGICAL THERAPY